Clinical Phase I study to assess safety tolerability, pharmacokinetics and pharmacodynamics of ATROSAB (Anti-TNF-receptor 1 monoclonal antibody) in response to single ascending intravenous infusion doses. A single center, randomized, double blind, parallel group and placebo-controlled clinical trial in healthy male subjects - ATR 001

Trial Profile

Clinical Phase I study to assess safety tolerability, pharmacokinetics and pharmacodynamics of ATROSAB (Anti-TNF-receptor 1 monoclonal antibody) in response to single ascending intravenous infusion doses. A single center, randomized, double blind, parallel group and placebo-controlled clinical trial in healthy male subjects - ATR 001

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Atrosab (Primary)
  • Indications Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Sepsis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Baliopharm AG
  • Most Recent Events

    • 09 Jun 2016 Status changed from recruiting to completed.
    • 09 Apr 2013 Status changed from not yet recruiting to recruiting.
    • 13 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top